Page 26 - Binder2

Because the cost of tolerization is not just measured in
dollars—it’s measured in broken continuity of care, in
diminished outcomes, and in eroded confidence. When
patients lose response, they don’t just lose efficacy. They
lose belief—in the drug, in the process, and sometimes in
the entire system built to help them. Rebuilding that trust
will take more than new molecules.

It will take a new contract between biotech innovation and
immune wisdom—one that doesn't treat rejection as
acceptable collateral, but as a solvable design flaw. That is
the promise of the next generation of biologics. And that is
where this story begins.

Because the cost of tolerization isn’t just financial. It’s the
cost of trust.

And we are running out of both.

1.5 – Coping Strategies (That Don’t
Work for Long)

When tolerization strikes—when a biologic stops
working—the response isn’t silence. It’s adjustment.
Clinicians, payers, and pharmaceutical companies all have
playbooks for how to respond. But almost every strategy in
circulation today shares the same flaw: they are reactive,
not preventive, and compensatory, not curative.

These are coping mechanisms—not solutions—and they
fail more often than we admit.

24